Sermorelin, tesamorelin, and ipamorelin are frequently grouped together because each is connected with the GH pathway. That grouping hides differences in mechanism, product approval, and clinical evidence. A useful comparison begins with the condition being treated, not a universal ranking of which peptide is strongest.
The EGRIFTA WR label identifies a specific tesamorelin indication: reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It is not an indication for general weight-loss management. Neither sermorelin nor ipamorelin acquires that evidence simply because it appears alongside tesamorelin in a comparison chart.
Tesamorelin’s approved indication is specific. It does not make all three peptides interchangeable or establish a best option for general fat loss or anti-aging.
The three-way overview
Swipe sideways to read the full table. You can also select the table and use the arrow keys.
| Topic | Sermorelin | Tesamorelin | Ipamorelin |
|---|---|---|---|
| Main signaling category | GHRH analog | GHRH analog | Ghrelin-receptor agonist |
| Key product distinction | Historical GEREF differs from current compounded preparations | Approved EGRIFTA products have specific labeling | Research and compounding claims need their own verification |
| Common evidence mistake | Calling any GHRH study a sermorelin trial | Applying HIV-lipodystrophy results to ordinary weight loss | Treating unrelated routes or study purposes as wellness evidence |
The sermorelin-versus-tesamorelin guide and sermorelin-versus-ipamorelin guide examine each pair in more depth. This overview is intended to make the distinctions visible before comparing an actual care plan.
Approval belongs to a product and indication
An approved tesamorelin product's label should not be used as the instructions for a compounded tesamorelin blend. Concentration, preparation, and other details can differ. Likewise, historical sermorelin approval does not establish approval of a new oral or injectable compounded product.
FDA's compounding questions and answers explain the general distinction. Ask the provider to identify the exact product and whether it is FDA-approved or compounded. The answer should refer to the medication being dispensed, not only the ingredient's name.
A hormone increase does not resolve a clinical comparison
Different studies can measure GH, IGF-1, body composition, symptoms, or function over very different periods. Comparing the largest hormone change across unrelated studies does not establish which treatment provides the best result for the same patient group.
Ask whether the study actually compares the drugs for your intended outcome. In the sources reviewed here, we did not identify a trial establishing a universal winner among these three for healthy adults seeking anti-aging benefits. The evidence guide explains why a mechanism or marker is only part of that question.
Ipamorelin research requires attention to route and purpose
FDA's 2024 ipamorelin evaluation discusses a limited and mixed body of evidence, including research that does not match typical subcutaneous wellness marketing. Evidence from an intravenous study for a different medical purpose cannot simply establish the benefits of a subcutaneous blend.
This is not a reason to assume that another product must be best. It is a reason to ask for an evidence trail that matches the proposed intervention. Similar names and shared hormonal effects cannot fill in missing trials or long-term outcome data.
Combination use is a separate decision
Putting two or three agents together does not create an evidence-based compromise between uncertain alternatives. Each additional ingredient changes the intervention and may complicate interpretation of effects. Our stacking guide covers the information needed to evaluate such a proposal.
Before paying, ask what diagnosis or goal justifies treatment, which exact product would be used, what relevant benefit is expected, and how safety and response would be reassessed. A comparison is most useful when it helps you ask those questions. It should not promise one peptide is universally best for every body, age, or treatment goal.
Sources & further reading
Provider pages describe offers; they do not independently establish treatment benefits. Sources checked September 20, 2026.
This article is education, not a diagnosis, prescription, or dosing plan. Discuss treatment and alternatives with a licensed clinician who knows your history. Compounded medications are not FDA-approved.